{"groups":[{"description":"TG-0054 (3.14 mg/kg)\n\nTG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)","id":"FG000","title":"TG-0054 (3.14 mg/kg TG-0054 Administrated Via 15-min IV Infus)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Duration of the Study:\n\nThis study will consist of a 14-day screening period, a 2- to 11-day treatment period, and a 7-day follow-up period.\n\nNumber of Patients:\n\nApproximately 12 treatment evaluable patients will be enrolled in this study.\n\nStudy Location: Single site in US."}